Evolving the evidence

Evolving the evidence
Evolving the evidence

 

Update to Cochrane Review based on new evidence

Cochrane Drugs and Alcohol

Aim: To discuss the evolution of the Cochrane review on Alcoholics Anonymous and other 12‐step programs for alcohol use disorder
Reason for evolution: New research 
Summary: In this interview, John Kelly, an author from Cochrane Drugs and Alcohol Review Group talks (among other things) about the decision to update the review on Alcoholics Anonymous and other 12‐step programs for alcohol use disorder. The decision was influenced by an increase in published research.  This new evidence strengthened the certainty in the results which allowed stronger conclusions to be reached, which potentially will allow a greater impact on decision making.  
Date: March 2020
Read more


Learnings from a Cochrane Review Group – looking across the portfolio of reviews

Cochrane Consumer and Communications

Aim: To present the learnings of developing a more strategic approach to managing a portfolio of Cochrane reviews.
Reason for evolution: Responding to stakeholder needs 
Summary: In this community blog, editors at the Cochrane Consumers and Communication Review Group talk about the changes they have made to increase control over their workload and to enable them to be more responsive to the needs of policy makers. This has involved applying the update classification to their reviews, retiring the reviews where the context means that the reviews are no longer applicable to current circumstances and involving stakeholders in the decisions around the priorities of the review group
Date: December 2017
Read more


Working with guideline developers to produce living recommendations

Cochrane Gynaecological, Neuro-oncology and Orphan Cancers

Aim: To show the development of three living systematic reviews which directly feed into living recommendations produced by guidelines.
Reason for evolution: Responding to stakeholder needs 
Summary: Authors from The Cochrane Gynaecological, Neuro-oncology and Orphan Cancers Review Group talk about how three existing systematic reviews were converted into ‘living systematic reviews’ in response to a collaboration with a national guideline developer, the American Society of Hematology. This allows guideline developers to access the latest evidence.
Date: June 2018
Read more